Several haematological malignancies, including multiple myeloma (MM) and acute myeloid leukaemia (AML), have well-defined precursor states that precede the development of overt cancer. MM is almost always preceded by monoclonal gammopathy of undetermined significance (MGUS), and at least a quarter of all patients with myelodysplastic syndromes (MDS) have disease that evolves into AML. In turn, MDS are frequently anteceded by clonal haematopoiesis of indeterminate potential (CHIP). The acquisition of additional genetic and epigenetic alterations over time clearly influences the increasingly unstable and aggressive behaviour of neoplastic haematopoietic clones; however, perturbations in the bone-marrow microenvironment are increasingly recognized to have key roles in initiating and supporting oncogenesis. In this Review, we focus on the concept that the haematopoietic neoplasia–microenvironment relationship is an intimate rapport between two partners, provide an overview of the evidence supporting a role for the bone-marrow niche in promoting neoplasia, and discuss the potential for niche-specific therapeutic targets.
Irene M. Ghobrial, et al.
Want To Publish your Group Article?
Click HERE to send us your group Article for publishing on our website.
- alzheimer Alzheimers Disease animal model Bacteria Brain breast cancer cancer cell & molecular biology cell-signaling clinical trials CRISPR CRISPR/Cas diabetes disease/medicine DNA drug drug development drug research Gene Expression general health Gene therapy Genetics genetics & genomics Genomics HIV immunology immunotherapy infectious disease Malaria metastasis microbiology microbiome mutation neuroscience new therapy obesity stem cells T cells techniques therapy treatment tumor vaccine virology virus